KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Microvision (MVIS) Asset Writedowns and Impairment (2016 - 2025)

Microvision's Asset Writedowns and Impairment history spans 12 years, with the latest figure at $10.1 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 1010100.0% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $13.1 million, up 334.03%, while the annual FY2025 figure was $10.1 million, 2393.83% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $10.1 million at Microvision, up from -$1000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $10.1 million in Q4 2025 and bottomed at -$44000.0 in Q3 2023.
  • The 4-year median for Asset Writedowns and Impairment is $27000.0 (2022), against an average of $1.2 million.
  • The largest annual shift saw Asset Writedowns and Impairment tumbled 101.56% in 2024 before it skyrocketed 1010100.0% in 2025.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $27000.0 in 2022, then surged by 137.04% to $64000.0 in 2023, then crashed by 101.56% to -$1000.0 in 2024, then surged by 1010100.0% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for MVIS's Asset Writedowns and Impairment are $10.1 million (Q4 2025), -$1000.0 (Q4 2024), and $13000.0 (Q3 2024).